An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.

Bethesda III category Bethesda IV cytology CytoFoam Core fine needle aspirate (FNA) immunoistochemestry indeterminate thyroid cytology thyroid nodule

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 23 10 2022
accepted: 16 11 2022
entrez: 19 12 2022
pubmed: 20 12 2022
medline: 21 12 2022
Statut: epublish

Résumé

Fine needle aspiration (FNA) is the procedure of choice in the evaluation of thyroid nodules. Nodules with indeterminate cytological categories, Bethesda III and IV, pose challenges in clinical practice and are frequently submitted to diagnostic surgery. CytoFoam Core (CFCS) uses an absorbent foam device inserted into the needle hub to collect the cytological sample aspirated during FNA. Specimen is formalin-fixed and paraffin-embedded. Assessing diagnostic efficacy of CFCS, compared to traditional cytology, in re-evaluating thyroid nodules classified as Bethesda III, using post-surgical histology as reference standard. Retrospective study on 89 patients with a first indeterminate cytological report who were referred to the Department of Endocrinology of Regina Apostolorum Hospital (Albano L. Rome, Italy) for a second FNA. FNA was performed after at least one month under ultrasound guidance with a 23G needle according to the established procedure. During the second procedure, both traditional cytological (TC) smears and a single-pass CFCS specimen were obtained for each patient. On CFCS samples immunocytochemical staining for Galectin-3, HBME-1, and CK-19 was also performed. 51 patients eventually underwent surgery, and their histological diagnoses were compared to the TC and CFCS reports. Four parameters were evaluated: inadequacy rate, rate of persistent indeterminate (Bethesda III and IV) reports, rate of malignancy in persistently indeterminate nodules, and rate of cancer in lesions cytologically classified as malignant. Non-diagnostic samples were 6 (11.8%) in TC vs 3 (5.9%) in CFCS (p=0.4). Persistent indeterminate samples were 31 (60.8%) in TC vs 19 (37.2%) in CFCS (p=0.01). Rate of malignancy in persistently indeterminate nodules was 8/19 (42.1%) in CFCS vs 9/31 (29%) in TC group (p=0.3). Nine/51 (17.6%) samples were classified as benign by TC vs 21/51 (41.2%) samples by CFCS (p<0.01). All nodules resulted benign at post-surgical evaluation. Five/51 (9.8%) samples were classified as suspicious for malignancy/malignant in TC group against 8/51 (15.7%) samples in CFCS (p=0.5). Post-surgical evaluation confirmed malignancy in all these cases. CFCS demonstrated greater diagnostic accuracy than TC in repeat FNA assessment of cytologically indeterminate nodules. CFCS increased the conclusive diagnosis rate and decreased the number of cytologically indeterminate cases.

Sections du résumé

Background
Fine needle aspiration (FNA) is the procedure of choice in the evaluation of thyroid nodules. Nodules with indeterminate cytological categories, Bethesda III and IV, pose challenges in clinical practice and are frequently submitted to diagnostic surgery. CytoFoam Core (CFCS) uses an absorbent foam device inserted into the needle hub to collect the cytological sample aspirated during FNA. Specimen is formalin-fixed and paraffin-embedded.
Aim of the study
Assessing diagnostic efficacy of CFCS, compared to traditional cytology, in re-evaluating thyroid nodules classified as Bethesda III, using post-surgical histology as reference standard.
Method
Retrospective study on 89 patients with a first indeterminate cytological report who were referred to the Department of Endocrinology of Regina Apostolorum Hospital (Albano L. Rome, Italy) for a second FNA. FNA was performed after at least one month under ultrasound guidance with a 23G needle according to the established procedure. During the second procedure, both traditional cytological (TC) smears and a single-pass CFCS specimen were obtained for each patient. On CFCS samples immunocytochemical staining for Galectin-3, HBME-1, and CK-19 was also performed. 51 patients eventually underwent surgery, and their histological diagnoses were compared to the TC and CFCS reports. Four parameters were evaluated: inadequacy rate, rate of persistent indeterminate (Bethesda III and IV) reports, rate of malignancy in persistently indeterminate nodules, and rate of cancer in lesions cytologically classified as malignant.
Results
Non-diagnostic samples were 6 (11.8%) in TC vs 3 (5.9%) in CFCS (p=0.4). Persistent indeterminate samples were 31 (60.8%) in TC vs 19 (37.2%) in CFCS (p=0.01). Rate of malignancy in persistently indeterminate nodules was 8/19 (42.1%) in CFCS vs 9/31 (29%) in TC group (p=0.3). Nine/51 (17.6%) samples were classified as benign by TC vs 21/51 (41.2%) samples by CFCS (p<0.01). All nodules resulted benign at post-surgical evaluation. Five/51 (9.8%) samples were classified as suspicious for malignancy/malignant in TC group against 8/51 (15.7%) samples in CFCS (p=0.5). Post-surgical evaluation confirmed malignancy in all these cases.
Conclusion
CFCS demonstrated greater diagnostic accuracy than TC in repeat FNA assessment of cytologically indeterminate nodules. CFCS increased the conclusive diagnosis rate and decreased the number of cytologically indeterminate cases.

Identifiants

pubmed: 36531453
doi: 10.3389/fendo.2022.1078019
pmc: PMC9752034
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1078019

Informations de copyright

Copyright © 2022 Taccogna, Papini, Novizio, D’Angelo, Turrini, Persichetti, Pontecorvi and Guglielmi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Acta Cytol. 2016;60(5):399-405
pubmed: 27764825
Cancers (Basel). 2022 Jul 10;14(14):
pubmed: 35884418
Head Neck Pathol. 2021 Mar;15(1):254-261
pubmed: 32077055
Thyroid. 2009 Nov;19(11):1159-65
pubmed: 19888858
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Eur Thyroid J. 2017 Sep;6(5):225-237
pubmed: 29167761
Endocrine. 2021 Jun;72(3):711-720
pubmed: 33030666
Endocrine. 2013 Oct;44(2):419-25
pubmed: 23334946
JAMA Oncol. 2019 Feb 1;5(2):204-212
pubmed: 30419129
J Clin Med. 2021 Sep 30;10(19):
pubmed: 34640574
Int J Surg. 2017 May;41 Suppl 1:S60-S64
pubmed: 28506415
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
South Med J. 2009 May;102(5):498-501
pubmed: 19373168
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
PLoS One. 2015 Jun 26;10(6):e0130138
pubmed: 26115096
Int J Surg. 2014;12 Suppl 1:S29-34
pubmed: 24859409
Ann Surg Oncol. 2006 Mar;13(3):425-32
pubmed: 16485160
Thyroid. 2014 Jul;24(7):1115-20
pubmed: 24684285
Cancers (Basel). 2021 Nov 07;13(21):
pubmed: 34771729
Diagn Pathol. 2015 Oct 26;10:196
pubmed: 26503236
Ann Ital Chir. 2010 Nov-Dec;81(6):403-10; discussion 410-1
pubmed: 21456476
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Am Soc Cytopathol. 2017 Nov - Dec;6(6):217-222
pubmed: 31043290
Mol Genet Genomic Med. 2020 Sep;8(9):e1288
pubmed: 32436637
Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64
pubmed: 16082252
BMC Surg. 2014 Mar 06;14:12
pubmed: 24597765

Auteurs

Silvia Taccogna (S)

Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.

Enrico Papini (E)

Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.

Roberto Novizio (R)

Endocrinology and Metabolism, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
Catholic University of the Sacred Heart, Rome, Italy.

Martina D'Angelo (M)

Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.

Luca Turrini (L)

Pathology, Ospedale Regina Apostolorum, Albano Laziale, Italy.

Agnese Persichetti (A)

Service of Pharmacovigilance, Regina Elena National Cancer Institute, Hospital Physiotherapy Institutes (IRCCS), Rome, Italy.

Alfredo Pontecorvi (A)

Endocrinology and Metabolism, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.
Catholic University of the Sacred Heart, Rome, Italy.

Rinaldo Guglielmi (R)

Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH